Literature DB >> 1380026

c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma.

J D Collier1, K Guo, J Mathew, F E May, M K Bennett, I P Corbett, M F Bassendine, A D Burt.   

Abstract

The c-erbB-2 proto-oncogene encodes a transmembrane protein which is homologous to the epidermal growth factor receptor. This protein can be localized immunohistochemically in formalin-fixed paraffin-embedded material using a monoclonal antibody NCL-CB11; positive membrane staining correlates with gene amplification and protein overexpression in breast cancer. Using this technique we have shown that only 2/26 (8%) of hepatocellular carcinomas, 0/10 (0%) of cholangiocarcinomas and 0/2 (0%) hepatoblastomas overexpressed c-erbB-2 as evidenced by membrane staining. Moreover c-erbB-2 mRNA was not detected in seven hepatocellular carcinomas examined by Northern blot analysis. c-erbB-2 overexpression is, therefore, unlikely to be contributing to the malignant phenotype in hepatocellular carcinoma and cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380026     DOI: 10.1016/0168-8278(92)90186-s

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

1.  Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

Authors:  Siobhan C McKay; Kristian Unger; Stephanos Pericleous; Gordon Stamp; Gerry Thomas; Robert R Hutchins; Duncan R C Spalding
Journal:  HPB (Oxford)       Date:  2011-03-10       Impact factor: 3.647

2.  NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.

Authors:  A E Sirica; S Radaeva; N Caran
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

3.  Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma.

Authors:  Z-H Xian; S-H Zhang; W-M Cong; W-Q Wu; M-C Wu
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

4.  Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression.

Authors:  Nicholas A Shackel; Peter H McGuinness; Catherine A Abbott; Mark D Gorrell; Geoffrey W McCaughan
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

Review 5.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

6.  Serum levels of c-erbB-2 protein in digestive diseases.

Authors:  Y Motoo; N Sawabu; Y Yamaguchi; I Mouri; O Yamakawa; H Watanabe; H Ohta; T Okai; H Makino
Journal:  J Gastroenterol       Date:  1994-10       Impact factor: 7.527

7.  The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma.

Authors:  Nuray Bassullu; Ilknur Turkmen; Murat Dayangac; Pinar Yagiz Korkmaz; Reyhan Yasar; Murat Akyildiz; Onur Yaprak; Yaman Tokat; Yildiray Yuzer; Gulen Bulbul Dogusoy
Journal:  Hepat Mon       Date:  2012-10-11       Impact factor: 0.660

8.  Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma.

Authors:  Y Ito; T Takeda; M Sakon; M Tsujimoto; S Higashiyama; K Noda; E Miyoshi; M Monden; N Matsuura
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

Review 9.  HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

Authors:  Salvatore Galdy; Angela Lamarca; Mairéad G McNamara; Richard A Hubner; Chiara A Cella; Nicola Fazio; Juan W Valle
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

Review 10.  HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.

Authors:  Nicola Fusco; Silvano Bosari
Journal:  World J Gastroenterol       Date:  2016-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.